S&P Futures
4,306.75 -1.00 (-0.02%) Dow Futures
34,125.00 +7.00 (+0.02%) Nasdaq Futures
13,643.00 -15.25 (-0.11%) Russell 2000 Futures
2,024.20 +0.90 (+0.04%) Crude Oil
86.93 +0.40 (+0.46%) Gold
1,790.40 +0.70 (+0.04%)
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW)
Chart Events
Performance Outlook
| Previous Close | 0.0500 |
| Open | 0.6501 |
| Bid | 0.6651 x 1800 |
| Ask | 0.7155 x 800 |
| Day's Range | 0.0700 - 0.1000 |
| 52 Week Range | 0.0700 - 0.1000 |
| Volume | |
| Avg. Volume | N/A |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
Reported positive topline results for ONWARD™ Phase 3 trial of AD04 for the treatment of Alcohol Use Disorder Pursuing submission of ONWARD™ results with both European and U.S. regulatory agencies Actively exploring potential partnership opportunities for AD04 Ended second quarter with cash and cash equivalents of $9.2 million CHARLOTTESVILLE, Va., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical com
- GlobeNewswire
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use Disorder
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking AD04 demonstrated statistically significant difference in AUD severity, as compared to placebo, with an 84% decrease in the number of heavy drinking patients meeting the criteria for AUD diagnosis Company plans to submit ONWARD results to both European and U.S. regulatory agencies Conference call
- GlobeNewswire
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use Disorder
Company to host conference call on Wednesday, July 20, 2022, at 1 PM ETCHARLOTTESVILLE, Va., July 18, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it plans to report topline results from the Company’s ONWARD™ Phase 3 clinical trial on Wednesday, July 20, 2022. The Company plan
